404
Hemophilia A and B Therapeutics Materials Market Analysis | 2021-2026
Hemophilia A and B Therapeutics Materials Market Growth, Trends, Dynamics & Market Insights: 2021-2026
Eagle Biologics, Inc. (US), Spark Therapeutics, Inc. (US), Alnylam Pharmaceuticals Inc. (US), San-gamo Therapeutics, Inc. (US), Novo Nordisk A/S (Denmark), Shire plc (US), The Chugai Pharma-ceutical Co., Ltd. (Japan), Bayer AG (Germany), CSL Behring (US) and Pfizer Inc. (US) are among the key players in the hemophilia A and B therapeutics materials market.
Increasing incidences of blood disorders is the prime factor driving the growth of hemophilia A and B therapeutics materials market.
The hospital's segment is expected to register significant growth in the hemophilia A and B therapeutics materials market in the coming years.
North America accounted for the largest share in the hemophilia A and B therapeutics materials market in 2020.